InvestorsHub Logo
icon url

plexrec

07/31/16 9:18 AM

#71723 RE: samk #71711

samk...agree and good post....vast potential still exists---company states nothing has changed with the fundamentals (Science)--people panicked and sold having expected "better results". Why would people in the trial agree to stay on drug for 2 more years if they weren't optimistic for continued progress? Still a believer and very long Avxl !!!!!!!
icon url

twiz0019

07/31/16 10:07 AM

#71739 RE: samk #71711

That is true samk, however, the dark cloud hanging over the company is the financing for the P2/3 trial. IMHO, the potential for a partnership has gone down significantly. The other 2 possibilities....LPC and dilution....will drive us down further. Yes, we are still better than donepezil.....however, the facts as we stand today are that the overall data has gone from cognitive improvement at 5 weeks to stability at 31 weeks.....that has taken a lot of air out of the balloon.
icon url

lt2211

07/31/16 11:23 AM

#71756 RE: samk #71711

I can't comment on what might happen in the long run, simply because I don't know. For now, though, the possibility of any big pharma, willing to partner, seems unlikely. Many Alzheimer's drug candidates, show promise early on, nearly all are unsuccessful. This stock has been plagued by typical "pump and dump" tactics which have been going on since the stock left penny land. Run the stock up on wild assertions of partner coming soon, $50 after results, Etc. Sell on or near the news, steal the suckers money. A scam as old as the hills and very prevalent in small biotech's about to report results.

Some where down the road, there may be facts to back up a partner or accelerated treatment by the FDA. In the short run, I don't see anything that would rise to that level. Other that a bit of "day dreaming"